Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

DNAPrint Genomics Inc

US DNAG

NoneUSD
0.00(0%)

Last update at 2026-06-04T21:52:25.568922Z

Day Range

--
LowHigh

52 Week Range

-0.0001
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap0.00064M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.77639M
  • Revenue TTM1.93M
  • Revenue Per Share TTM0.004
  • Gross Profit TTM 0.75M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2006-12-31 2005-12-31 2004-12-31 2003-12-31 2002-12-31
Type yearly yearly yearly yearly yearly
Date 2006-12-31 2005-12-31 2004-12-31 2003-12-31 2002-12-31
Income before tax -12.34836M -8.71585M -3.73498M -7.78991M -
Minority interest - - - - -
Net income -12.34836M -8.71585M -3.73498M -7.78991M -
Selling general administrative 3.19M 2.86M 2.05M 3.86M -
Selling and marketing expenses - - - - -
Gross profit 0.75M 0.33M 0.28M 0.28M -
Reconciled depreciation - - - - -
Ebit -8.86717M -4.66190M -3.33442M -6.23477M -
Ebitda - - - - -
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -8.86717M -4.66190M -3.33442M -6.23477M -
Other operating expenses - - - - -
Interest expense 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00000M 0.00000M 0.00000M 0.00000M -
Total revenue 2.43M 1.28M 0.79M 0.71M 0.18M
Total operating expenses 11.30M 5.94M 4.12M 6.94M -
Cost of revenue 1.68M 0.95M 0.51M 0.43M 2.62M
Total other income expense net -3.48120M -4.05395M -0.40056M -1.55513M -
Discontinued operations - - - - -
Net income from continuing ops -12.34836M -8.71585M -3.73498M -7.78991M -
Net income applicable to common shares -12.34836M -8.71585M -3.73498M -7.78991M -
Preferred stock and other adjustments - - - - -
Breakdown 2006-12-31 2005-12-31 2004-12-31 2003-12-31 2002-12-31
Type yearly yearly yearly yearly yearly
Date 2006-12-31 2005-12-31 2004-12-31 2003-12-31 2002-12-31
Total assets 10.27M 6.31M 1.79M 1.29M 0.42M
Intangible assets 0.23M 0.33M - - -
Earning assets - - - - -
Other current assets 0.06M 0.14M 0.12M 0.22M 0.01M
Total liab 13.98M 10.40M 1.70M 3.33M 1.53M
Total stockholder equity -3.71063M -4.09028M 0.10M -2.03709M -
Deferred long term liab - - - - -
Other current liab 2.52M 7.18M 0.04M 0.06M -
Common stock 4.58M 2.36M 9.39M 5.24M 4.51M
Capital stock - - - - -
Retained earnings -45.52995M -36.50604M -27.79019M -24.05521M -
Other liab - 0.05M - 0.31M -
Good will - 0.33M - - -
Other assets 0.02M 0.00970M 0.00500M 0.00500M 0.00500M
Cash 0.59M 1.81M 0.98M 0.27M 0.01M
Cash and equivalents - - - - -
Total current liabilities 13.77M 10.05M 1.57M 2.54M 1.53M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt 0.24M 1.07M 0.16M 0.83M -
Short long term debt 0.24M 1.07M 0.16M 0.83M -
Short long term debt total - - - - -
Other stockholder equity 5.79M 0.03M 0.32M 0.42M -
Property plant equipment 1.24M 1.23M 0.38M 0.28M 0.38M
Total current assets 8.78M 2.47M 1.41M 1.00M -
Long term investments - 2.27M - - -
Net tangible assets -3.93574M -4.41624M 0.10M -2.03709M -
Short term investments 7.90M - - - -
Net receivables 0.07M 0.10M 0.24M 0.43M -
Long term debt 0.18M 0.13M 0.03M 0.47M -
Inventory 0.10M 0.30M 0.07M - -
Accounts payable 3.01M 1.15M 0.35M 0.58M 0.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total - - - - -
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2006-12-31 2005-12-31 2004-12-31 2003-12-31 2002-12-31
Type yearly yearly yearly yearly yearly
Date 2006-12-31 2005-12-31 2004-12-31 2003-12-31 2002-12-31
Investments 0.55M -2.27470M -2.27470M -2.27470M -
Change to liabilities 2.03M 0.78M -0.96676M 1.54M 0.42M
Total cashflows from investing activities 0.16M -2.19592M -0.25065M -0.01417M -
Net borrowings 1.37M 2.30M -0.14856M 0.65M -
Total cash from financing activities 4.41M 6.63M 4.73M 1.38M 1.55M
Change to operating activities 0.08M 0.04M -0.06501M -1.02943M -
Net income -12.34836M -8.71585M -3.73498M -7.78991M -
Change in cash -1.21196M 0.83M 0.71M 0.25M -
Begin period cash flow - - - - -
End period cash flow - - - - -
Total cash from operating activities -5.78179M -3.60588M -3.76443M -1.10686M -
Issuance of capital stock - - - - -
Depreciation 0.54M 0.22M 0.18M 0.13M -
Other cashflows from investing activities 0.55M 0.20M -0.19368M -0.19368M -
Dividends paid - - - - -
Change to inventory 0.20M -0.22286M -0.06528M -0.06528M -
Change to account receivables 0.03M -0.01065M -0.03426M 0.00206M -
Sale purchase of stock 3.03M 4.46M 4.60M 0.48M -
Other cashflows from financing activities - -0.13500M -0.13500M 0.24M 0.09M
Change to netincome 3.44M 3.97M 0.90M 6.05M -
Capital expenditures 0.39M 0.12M 0.06M 0.01M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - - - - -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow - - - - -

Peer Comparison

Sector: Industry:

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
DNAG
DNAPrint Genomics Inc		 - -% - - - 0.0003 -
DOGEF
Orsted A/S		 - -% 22.01 28.82 0.66 6.50 0.07 3.88 15.58
NCRRP
NCR Corp Pref A		 - -% 1002.00 1034.35 - - -
TBB
AT&T Inc. 5.35% GLB NTS 66		 - -% 20.53 4.60 - - -
CCZ
Comcast Holdings Corp		 -0.95 1.45% 64.55 55.07 - - -

Reports Covered

Stock Research & News

View All

Profile

DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services. It offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA, which measures European sub-ancestry; EuropeanDNA, which reports a customer's proportional basic continental European ancestry; DNAWitness to determine genetic heritage from DNA samples obtained from crime scenes; RETINOME, which provides a physical portrait of a person of interest for a detective based on a DNA sample from a crime scene or remains of an individual; RETINOME, which allows infer eye color from DNA; and GenomeLab SNPstream Genotyping System, which offers genotyping rates and uses a multiplexing format to generate data with the minimum of reagents. The company serves forensic science, genealogical research, consumer products, and pharmaceutical development clients. DNAPrint Genomics, Inc. was formerly known as Lexington Energy, Inc. The company was incorporated in 1983 and is based in Sarasota, Florida with a subsidiary in Leverkusen, Germany.

DNAPrint Genomics Inc

1621 West University Parkway, Sarasota, FL, United States, 34243

  • 941-366-3400
  • Employees : 24

Key Executives

Name Title Year Born
Mr. Jatin Patel Exec. Officer NA
Dr. Laurence A. Rubin M.D., FRCPC FACP Exec. Officer NA
Mr. Naz Jiwani BBA, CIRM Exec. Officer NA
Ms. Pauline Gula Exec. Officer NA
Mr. Zach Gaskin Exec. Officer NA
Ms. Emanuela Charlton Exec. Officer NA
Ms. Lisa Tandy Herren Exec. Officer NA
Mr. Scot Alic Exec. Officer NA
Mr. Shannon Boyd Exec. Officer NA
Dr. Hector de Jesus Ruiz Exec. Officer 1946

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions